Klara Is Acquired by ModMed

Klara, a leader in patient communication and collaboration whose platform empowers patients to take more control of their healthcare experience and practices to increase efficiency has been acquired by ModMed.

Klara’s platform is designed to enable collaboration and communication between practice and patient, including how patients discover, select and engage with a provider. The capability for practices and patients to collaborate digitally has never been more important.

“We are in the midst of one of healthcare’s greatest shifts and Klara is a leading innovator toward a more patient-centric experience,” said Dan Cane, Chief Executive Officer of ModMed. “Frankly, we believe this is a new category. We see a future where unified collaboration platforms will create a more convenient and frictionless environment – where conversations and the data they contain flow directly into EHR and PM systems while also connecting back to patients and practices and third-party providers like pharmacies, labs, and insurance companies.”

Cane added, “We believe that this more convenient and frictionless environment can fundamentally improve interactions, involvement and ownership of healthcare outcomes across the ecosystem.”

Between the pandemic, staff shortages, population growth, and the rise of aging boomers, healthcare workers are burning out at an alarming rate. When coupled with growing consumer demand for technologies that help patients take a more active role in their care, the healthcare industry can benefit from innovative solutions that better support the medical community and further empower patients.

ModMed is well-known for its deep focus on healthcare technology research and development and for taking a customer-led approach to helping providers create efficiencies and save time,” said Simon Bolz, Co-Founder of Klara.

Dr. Simon Lorenz, also Co-Founder of Klara, added: “We look forward to leveraging our expertise as well as technology and working together to deliver even better patient-centric innovations so that we continue to improve the experience for all patients.”

Cane continued, “We are beyond excited to help shape this next frontier which has the potential to alleviate pressures on healthcare workers, give greater control to patients, and improve on healthcare collaboration throughout the industry.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version